Q2 2026 13F · SEC CIK 1281446

Great Point Partners LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $424.4M
Reported positions: 37
Top holdings a year, 3 yrs: +46.0%
Assets under management: $1.8B

Great Point Partners LLC is a hedge fund that reported 37 positions worth $424.4M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Vor Biopharma Inc (VOR, 7.4%), Abivax SA (ABVX, 6.4%), Vera Therapeutics Inc Class A (VERA, 6.1%). A portfolio copying its top holdings returned 46.0% a year over the last 3 years, against 20.4% for the S&P 500.

Great Point Partners LLC holdings all 37 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Great Point Partners LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
VORVor Biopharma Inc	7.4%	7.6%	1,700,000	-2.9%	$31.3M
ABVXAbivax SA	6.4%	New	204,314	—	$27.2M
VERAVera Therapeutics Inc Class A	6.1%	2.0%	600,836	+201.4%	$25.8M
ZURAZura Bio Ltd	5.9%	6.1%	4,215,930	+0.0%	$24.9M
ALMSAlumis Ord	5.7%	4.6%	856,061	+0.0%	$24.1M
SLGLSol-Gel Technologies Ltd	4.8%	5.3%	274,363	+0.0%	$20.3M
24477V105Definium Therapeutics Inc	4.7%	New	425,000	—	$20.0M
ANNXAnnexon Inc	4.7%	3.4%	3,500,000	+40.0%	$20.0M
ORKAOruka Therapeutics Inc	4.1%	2.2%	183,330	+0.0%	$17.4M
MLTXMoonlake Immunotherapeutics	3.9%	2.3%	855,813	+71.2%	$16.7M
SGMTSagimet Biosciences Inc	3.7%	New	2,029,933	—	$15.7M
CTNMContineum Therapeutics Inc	3.6%	2.6%	921,481	+15.2%	$15.1M
IMMXImmix Biopharma Inc	3.1%	0.8%	1,277,642	+265.0%	$13.2M
CLYMClimb Bio Inc	3.1%	2.2%	1,000,000	-25.0%	$13.0M
AMLXAmylyx Pharmaceuticals Inc	3.0%	6.0%	700,000	-60.0%	$12.6M
NKTRNektar Therapeutics	2.9%	5.6%	175,000	-44.7%	$12.2M
NGNENeurogene Inc	2.6%	2.5%	352,180	-29.6%	$11.1M
LBRXLB Pharmaceuticals, Inc.	2.4%	1.8%	317,221	+5.7%	$10.3M
IRDOpus Genetics Inc	1.9%	0.4%	1,970,187	+507.4%	$8.1M
EPRXEupraxia Pharmaceuticals Inc	1.9%	2.1%	1,200,000	+0.0%	$7.9M
10919W405Bright Minds Biosciences Inc	1.8%	3.9%	109,603	-50.2%	$7.7M
N44821101Inflarx NV	1.6%	New	3,046,557	—	$6.8M
RLMDRelmada Therapeutics Inc	1.4%	1.4%	842,106	+0.0%	$5.8M
JATTJatt II Acquisition Corp	1.3%	New	500,000	—	$5.7M
CGEMCullinan Therapeutics Inc	1.3%	1.0%	300,000	+0.0%	$5.5M
ALTAltimmune Inc	1.2%	New	1,741,232	—	$5.3M
AMANAmanat Acquisition Corp	1.2%	New	500,000	—	$5.1M
RZLTRezolute, Inc.	1.2%	0.7%	951,809	+0.0%	$4.9M
SLNSilence Therapeutics PLC	1.2%	1.3%	450,000	-55.9%	$4.9M
PALIPalisade Bio Inc	1.1%	1.5%	2,284,819	-32.9%	$4.8M
EVMNEvommune Inc	1.0%	1.8%	325,000	+0.0%	$4.3M
SCYXScynexis Inc	0.9%	New	944,292	—	$3.8M
ELVNEnliven Therapeutics Inc	0.8%	New	70,000	—	$3.6M
HUMAHumacyte, Inc.	0.7%	0.6%	3,750,000	+0.0%	$2.9M
RNTXRein Therapeutics Inc	0.6%	New	2,575,000	—	$2.7M
DBVTDbv Technologies S A	0.6%	New	156,906	—	$2.6M
PMNPromis Neurosciences Inc	0.3%	1.2%	86,150	-76.8%	$1.1M

What Great Point Partners LLC bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +93.1% /yr; S&P 500 +20.1%
3 years: +46.0% /yr; S&P 500 +20.4%
5 years: +27.0% /yr; S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$424.4M	37
Q1 2026	$408.3M	39
Q4 2025	$308.4M	29
Q3 2025	$239.5M	28
Q2 2025	$153.8M	26
Q1 2025	$184.0M	31
Q4 2024	$212.2M	26
Q3 2024	$331.4M	29
Q2 2024	$522.0M	33
Q1 2024	$641.6M	35
Q4 2023	$586.7M	34
Q3 2023	$531.6M	39

Questions about Great Point Partners LLC's portfolio

What stocks does Great Point Partners LLC own?

Great Point Partners LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 37 positions worth $424.4M. The largest are Vor Biopharma Inc (VOR) at 7.4%, Abivax SA (ABVX) at 6.4%, Vera Therapeutics Inc Class A (VERA) at 6.1%, Zura Bio Ltd (ZURA) at 5.9% and Alumis Ord (ALMS) at 5.7%.

What did Great Point Partners LLC buy last quarter?

In Q2 2026, Great Point Partners LLC added a new position in Abivax SA (ABVX), a new position in Definium Therapeutics Inc, a new position in Sagimet Biosciences Inc (SGMT), a new position in Inflarx NV, a new position in Jatt II Acquisition Corp (JATT), Opus Genetics Inc (IRD) (+507.4% shares), Immix Biopharma Inc (IMMX) (+265.0% shares) and Vera Therapeutics Inc Class A (VERA) (+201.4% shares), compared with its Q1 2026 filing.

What did Great Point Partners LLC sell last quarter?

In Q2 2026, Great Point Partners LLC sold all of Apogee Therapeutics Inc (APGE), sold all of Kalvista Pharmaceuticals Inc (KALV), sold all of Immunovant Inc (IMVT), sold all of Jade Biosciences Inc, sold all of Zenas Biopharma Inc (ZBIO), Promis Neurosciences Inc (PMN) (-76.8% shares), Amylyx Pharmaceuticals Inc (AMLX) (-60.0% shares) and Silence Therapeutics PLC (SLN) (-55.9% shares), compared with its Q1 2026 filing.

How has Great Point Partners LLC's portfolio performed?

A portfolio copying Great Point Partners LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +46.0% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +93.1% against +20.1%. Over 5 years: +27.0% a year against +11.6%.

When is Great Point Partners LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Great Point Partners LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Great Point Partners LLC manage?

Great Point Partners LLC reported $1.8B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $424.4M.